Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE | BSE: 532321) reported a strong set of earnings for the quarter ended September 30, 2025, with consolidated net profit rising 38% year-on-year (YoY) to ₹1,258.6 crore. The growth was driven by solid performance across the company’s formulations and wellness businesses.
Revenue from operations increased 17% YoY to ₹6,123.2 crore, compared to ₹5,237 crore in the same period last year. On a sequential basis, revenue declined 6.9% from ₹6,573.7 crore in Q1FY26.
The company’s EBITDA stood at ₹2,015.8 crore, up 37.9% YoY, while the EBITDA margin improved to 32.9%. Profit before tax rose 32.8% to ₹1,687.4 crore.
For the first half of FY26, Zydus reported revenue of ₹12,696.9 crore, reflecting an 11% YoY increase. EBITDA rose 16% to ₹4,104.3 crore with margins expanding to 32.3%. Net profit for the period stood at ₹2,725.4 crore, up 17% YoY. The company also incurred ₹893 crore in organic capital expenditure during the first half of the fiscal year.
Zydus maintained a strong financial position with a net debt-to-equity ratio of 0.09x and a net debt-to-EBITDA ratio of 0.3x, underscoring its sound financial discipline and healthy balance sheet.